We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




HPV Testing Offers Women Longer Protection than Smear Testing

By Labmedica staff writers
Posted on 21 May 2008
Testing for human papillomavirus (HPV) can be twice as effective at protecting women from developing cervical abnormalities as smear testing.

Nearly 3000 women aged 35+ were recruited into a study between April 1994 and September 1997. More...
They were asked to participate in the study in which HPV testing would be performed in addition to cytology (smear test) whilst attending their general practitioner (GP) practice (40 practices were involved in the trial) for a routine cervical smear.

All women tested were followed up passively using data from the national computerized system that records all smears and their results--the Open-Exeter system. Women with a smear history indicating the need for colposcopy--a more thorough examination of the cervix--were investigated further to determine whether the colposcopy and biopsy were performed, and what the resultant outcome was. Passive follow-up was complete for all women by early 2005.

Results showed that the risk of developing cervical abnormalities at one, five, and nine years after a normal smear test was 0.33%, 0.83%, and 2.20% respectively, with those odds significantly reduced after a negative HPV test--0.19%, 0.42%, and 1.88%, respectively.

The study was led by Prof. Jack Cuzick of Barts and The London School of Medicine and Dentistry (London, UK) and the results were published on May 15, 2008, in the International Journal of Cancer.

Prof. Cuzick said that HPV testing "offers women excellent protection from cervical abnormalities for at least six years after a negative test, compared to protection from a normal smear test which begins to wane after about three years. This suggests that the screening interval can be safely extended to at least six years with HPV testing. These data provide more support for replacing screening based on abnormal cells, with a more sensitive test based on screening for the human papillomavirus.”


Related Links:
Barts and The London School of Medicine and Dentistry

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.